Diabetes Care, Vol 16, Issue 7 1035-1038, Copyright © 1993 by American Diabetes Association

ARTICLES

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients

JC Chan, B Tomlinson, JA Critchley, CS Cockram and RJ Walden
Department of Clinical Pharmacology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, N.T.

OBJECTIVE--To compare the metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. RESEARCH DESIGN AND METHODS--After a 2-wk run-in period on dietary treatment alone, 12 Chinese normotensive patients with uncomplicated NIDDM were randomized to receive either metformin, or glibenclamide for 4 wk before being crossed-over to the alternative treatment for an additional 4 wk. Metabolic and hemodynamic index, including cardiac output estimation by impedance cardiography, were measured at baseline and at the end of each treatment period. RESULTS--Body mass index was reduced more with metformin than with glibenclamide, although glycemic control was similar with both drugs. Plasma total cholesterol concentration fell more with metformin (mean difference -0.65 mM, 95% confidence interval -0.96 to -0.32) than glibenclamide (mean difference -0.20 mM, 95% confidence interval -0.54-0.12) (P < 0.05). Compared with baseline values, erect diastolic blood pressure was reduced more by metformin (12.9% [95% confidence interval -21.5 to -4.4%]) than glibenclamide (-6.8% [95% confidence interval -14.9 to 1.2%]) (P < 0.001). The relative changes in the systemic vascular resistance index also differed between the two treatments (glibenclamide, 6.2 [-4.3 to 16.6%]; metformin, -1.2 [95% confidence interval -8.8-6.4%]) (P < 0.05)]. CONCLUSIONS--In normotensive NIDDM patients, treatment with metformin was associated with greater reductions in body weight, plasma total cholesterol concentration, and erect diastolic blood pressure, whereas the systemic vascular resistance index increased after treatment with glibenclamide. These findings merit long-term investigation.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				M. Santure, M. Pitre, N. Gaudreault, A. Marette, A. Nadeau, and H. Bachelard Effect of metformin on the vascular and glucose metabolic actions of insulin in hypertensive rats Am J Physiol Gastrointest Liver Physiol, May 1, 2000; 278(5): G682 - G692. [Abstract] [Full Text] [PDF]

				J. D. Peuler Opposing adrenergic actions of intravenous metformin on arterial pressure in female spontaneously hypertensive rats Cardiovasc Res, July 1, 1999; 43(1): 237 - 247. [Abstract] [Full Text] [PDF]

				M. S. Muntzel, I. Hamidou, and S. Barrett Metformin Attenuates Salt-Induced Hypertension in Spontaneously Hypertensive Rats Hypertension, May 1, 1999; 33(5): 1135 - 1140. [Abstract] [Full Text] [PDF]

				C. E. Schotborgh and A. A.M. Wilde ATP-Sensitive Potassium Channel Openers and Blockers in the Cardiovascular System: Physiology, Pharmacology, and Clinical Effects Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 243 - 255. [Abstract] [PDF]

				M. S. Muntzel, A. Abe, and J. S. Petersen Effects of Adrenergic, Cholinergic and Ganglionic Blockade on Acute Depressor Responses to Metformin in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 618 - 623. [Abstract] [Full Text]

				J. S. Petersen, W. Liu, D. R. Kapusta, and K. J. Varner Metformin Inhibits Ganglionic Neurotransmission in Renal Nerves Hypertension, May 1, 1997; 29(5): 1173 - 1177. [Abstract] [Full Text]

				T. A. Kotchen Attenuation of Hypertension by Insulin-Sensitizing Agents Hypertension, August 1, 1996; 28(2): 219 - 223. [Full Text]

				J. S. Petersen and G. F. DiBona Acute Sympathoinhibitory Actions of Metformin in Spontaneously Hypertensive Rats Hypertension, March 1, 1996; 27(3): 619 - 625. [Abstract] [Full Text]